[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 584
Citations 0
Comment & Response
January 12, 2016

Tinzaparin vs Warfarin for Acute Venous Thromboembolism—Reply

Alok A. Khorana, MD1; Agnes Y. Y. Lee, MD, MSc2; For the CATCH Steering Committee
Author Affiliations
  • 1Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
  • 2Division of Hematology, Department of Medicine, University of British Columbia, Vancouver, Canada
JAMA. 2016;315(2):200-201. doi:10.1001/jama.2015.15070

In Reply Ms Maruyama and colleagues question the conclusions of the CATCH trial of tinzaparin vs warfarin for the treatment of cancer-associated venous thromboembolism and raise concerns with the reporting of serious adverse events and mortality. We note that the CATCH trial was the largest study of treatment of acute venous thromboembolism in patients with active malignancy ever conducted and included a diverse study population, thereby increasing its generalizability and validity in the real-world setting. All safety and efficacy analyses were conducted with intention to treat, capturing all 900 randomized patients.

First Page Preview View Large
First page PDF preview
First page PDF preview
×